Nubain, Nalbuphine

Nubain, Nalbuphine Newswire

Comprehensive Real-Time News Feed for Nubain, Nalbuphine (generic).

Results 1 - 20 of 31 in Nubain, Nalbuphine (generic)

  1. Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Prurigo NodularisRead the original story

    Tuesday Mar 10 | BioSpace

    Trevi Therapeutics, Inc. , a late stage clinical development company developing Nalbuphine ER for chronic pruritus conditions, today announced the initiation of the Company's pivotal study of Nalbuphine ER in patients with prurigo nodularis , a severely pruritic dermatological condition characterized by itchy skin nodules. The Company is also currently conducting a pivotal trial with Nalbuphine ER in hemodialysis patients with uremic pruritus , which is almost fully enrolled.

    Comment?

  2. 2 nabbed for illegal drug possessionRead the original story w/Photo

    Feb 24, 2015 | Sun-Star

    Arrested in Barangay Sawang Calero was Roy Aldrich Jurado, 27, a resident of the said village, while police nabbed in Barangay Zapatera 24-year-old Alfe Dela Cruz Saquilabon, a resident of Sitio Nivels Hills Barangay Apas. It was Jurado's brother, Kim Christian, who notified the Police Station 6 after he found drug paraphernalia among the suspect's belongings.

    Comment?

  3. Use of an organotypic mammalian in vitro follicle growth assay to...Read the original story

    Feb 18, 2015 | CSIRO Publishing

    More robust and efficient methods to assess these effects are needed. Herein we adapted and validated an organotypic in vitro follicle growth assay to determine the impact of compounds on markers of ovarian function.

    Comment?

  4. Trevi Therapeutics to Present at the Annual Cowen and Company Healthcare ConferenceRead the original story

    Feb 23, 2015 | Freshnews

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced that Jennifer Good, President and Chief Executive Officer, will present a corporate overview of Trevi at the Cowen and Company 35th Annual Health Care Conference, March 2-4, 2015 at The Boston Marriott Copley Place. Ms. Good will present on Monday, March 2nd at 10:00 am.

    Comment?

  5. Humanwell Healthcare (Group) Co., Ltd. (600079) - Financial and...Read the original story

    Feb 12, 2015 | PR-inside.com

    The company develops, produces and distributes pharmaceutical, medical instrument and reproductive health care products and technologies. Its products include pethidine hydrochloride, compound mifepriston, cyproterone acetate, deproteinized calf blood extractives, midazolam, human immunoglobulin intravenous, rapivacaine HCI, three vitamins and nysfungin, chuanbei qingfei, tongzhi surunjiang, fentanyl citrate, recombiant human erythropoietin, paracetamol and tramadol hydrochloride, nalbuphine hydrochloride, among others.

    Comment?

  6. Humanwell Healthcare (Group) Co., Ltd. (600079) - Pharmaceuticals &...Read the original story

    Feb 4, 2015 | PR-inside.com

    The company develops, produces and distributes pharmaceutical, medical instrument and reproductive health care products and technologies. Its products include pethidine hydrochloride, compound mifepriston, cyproterone acetate, deproteinized calf blood extractives, midazolam, human immunoglobulin intravenous, rapivacaine HCI, three vitamins and nysfungin, chuanbei qingfei, tongzhi surunjiang, fentanyl citrate, recombiant human erythropoietin, paracetamol and tramadol hydrochloride, nalbuphine hydrochloride, among others.

    Comment?

  7. Budding Biotech In New Haven Receives $15 Million LoanRead the original story w/Photo

    Jan 8, 2015 | The Hartford Courant

    A budding pharmaceutical company in New Haven received a $15 million loan that will allow it to finish clinical trials on a treatment for chronic itching associated with kidney dialysis and, separately, a rare skin condition marked by hard, crusty bumps. Trevi Therapeutics Inc. of New Haven was formed in 2012 and is in late-stage development of its drug, Nalbuphine ER.

    Comment?

  8. Trevi Therapeutics Closes $15 Million Debt Facility Provided by Solar Capital and Square 1 BankRead the original story

    Jan 7, 2015 | Venture Capital Access Online

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender. 'This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis,' said Jennifer Good, President and CEO.

    Comment?

  9. Trevi Therapeutics Closes $15 Million Debt Facility Provided By AndRead the original story

    Jan 7, 2015 | BioSpace

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender. "This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis," said Jennifer Good, President and CEO.

    Comment?

  10. Trevi closes $15 mln loan from Solar Capital and Square 1 BankRead the original story w/Photo

    Jan 8, 2015 | PE Hub

    January 8, 2015 - Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender. "This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis," said Jennifer Good, President and CEO.

    Comment?

  11. Trevi Therapeutics Closes $15 Million Debt Facility Provided by Solar...Read the original story w/Photo

    Jan 8, 2015 | Investor's Business Daily

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender. "This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis," said Jennifer Good, President and CEO.

    Comment?

  12. Trevi Therapeutics To Present At The Healthcare ConferenceRead the original story

    Jan 4, 2015 | BioSpace

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced that Jennifer Good, President and Chief Executive Officer, will present a corporate overview of Trevi at the 33rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA on Thursday, January 15, 2015 at 8:30 am ET.

    Comment?

  13. Antinociceptive and cytotoxic activities of an epiphytic medicinal orchid: Vanda tessellata Roxb.Read the original story

    Dec 3, 2014 | BioMed Central

    Vanda tessellata has been used in different sorts of ailments such as inflammations, rheumatism, dysentery, bronchitis, dyspepsia and fever in folk medicine. In this study we evaluated the antinociceptive and cytotoxic effect of methanol and aqueous extracts of V. tessellata leaf.

    Comment?

  14. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Nov 17, 2014 | Business Wire

    Company units were up 2.6%. )--Clear Channel Spectacolor, bedrijfsonderdeel van Clear Channel Outdoor , dochtermaatschappij van iHeartMedia Inc. , heeft vandaag het grootste, mee... )--Fitch Ratings has assigned an 'A+' rating to Duke Energy Progress, Inc.'s proposed new $700 million dual tranche offering of first mortgage bonds.

    Comment?

  15. Trevi Therapeutics to Present at the Stifel 2014 Healthcare ConferenceRead the original story

    Nov 17, 2014 | Business Wire

    Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus . Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions.

    Comment?

  16. Clinical Trial Website Launches in Support of Pivotal Trial in Prurigo NodularisRead the original story

    Nov 14, 2014 | Freshnews

    MediciGlobal has launched a new website on behalf of Trevi Therapeutics, Inc. to provide access to information on a clinical trial for prurigo nodularis, considered one of the most severe forms of pruritus . Prurigo nodularis, also known as nodular prurigo, is characterized by painful nodules that itch so intensely that the perpetual cycle of itch, scratch, bleed, and scarring lasts for years or even decades.

    Comment?

  17. Trevi Therapeutics Selected to Exhibit Poster at American Society of Nephrology Kidney Week 2014Read the original story

    Nov 11, 2014 | Customer Interaction Solutions

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, was selected to exhibit a poster at the American Society of Nephrology's Kidney Week 2014 , which takes place November 13th-16th at the Pennsylvania Convention Center in Philadelphia, PA. Poster #TH-PO730, titled " Exploring Clinical and Pharmacological Effects of Nalbuphine HCl Oral Tablets in Hemodialysis Subjects wth Pruritus, " reports that Nalbuphine administered as oral nalbuphine HCl ER tablets was safe and well tolerated up to 240 mgs and that there appeared to be a dose-dependent reduction in VAS scores related to itch.

    Comment?

  18. TPG Biotech backs Trevi TherapeuticsRead the original story w/Photo

    Nov 7, 2014 | PE Hub

    Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors. The Company is continuing enrollment in the U.S. for its uremic pruritus trial, a pivotal study expected to enroll approximately 360 patients, and expects to initiate enrollment at European sites for this study by year-end.

    Comment?

  19. Trevi Therapeutics Announces Second Closing of $26 Million Series B...Read the original story

    Nov 5, 2014 | Venture Capital Access Online

    Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors. The Company is continuing enrollment in the U.S. for its uremic pruritus trial, a pivotal study expected to enroll approximately 360 patients, and expects to initiate enrollment at European sites for this study by year-end.

    Comment?

  20. Trevi Therapeutics Reels In $26 MillionRead the original story

    Nov 6, 2014 | BioSpace

    Trevi Therapeutics Announces Second Closing of $26 Million Series B Financing for Development of Nalbuphine ER Uremic pruritus trial enrolling ahead of schedule and Company preparing to initiate trial in prurigo nodularis NEW HAVEN, Conn.-- --Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors.

    Comment?